CALCA and parasitic infectious disease: Proposed measures including i) closely monitoring patients treated with anti-CGRP/CGRPR drugs, especially those prone to certain viral, bacterial and parasitic infections, and ii) the use of tailored dosages, in a gradual dose vs. symptom alleviation-dependent manner are strongly recommended.